Patents by Inventor Jan Grunewald
Jan Grunewald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10787480Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: June 12, 2019Date of Patent: September 29, 2020Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Publication number: 20190382441Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: June 12, 2019Publication date: December 19, 2019Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Patent number: 10392421Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: April 24, 2018Date of Patent: August 27, 2019Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Patent number: 10280139Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: November 27, 2017Date of Patent: May 7, 2019Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Publication number: 20180244717Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: April 24, 2018Publication date: August 30, 2018Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
-
Publication number: 20180155281Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: November 27, 2017Publication date: June 7, 2018Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia OU, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Patent number: 9988420Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: December 17, 2014Date of Patent: June 5, 2018Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang, Yunho Jin
-
Patent number: 9938323Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.Type: GrantFiled: November 5, 2015Date of Patent: April 10, 2018Assignee: Novartis AGInventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
-
Patent number: 9884817Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: GrantFiled: June 11, 2015Date of Patent: February 6, 2018Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Publication number: 20170355731Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.Type: ApplicationFiled: November 5, 2015Publication date: December 14, 2017Inventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
-
Publication number: 20170218085Abstract: The present invention provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.Type: ApplicationFiled: January 10, 2017Publication date: August 3, 2017Applicant: Novartis AGInventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Badry BURSULAYA
-
Publication number: 20170121282Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: June 11, 2015Publication date: May 4, 2017Applicant: NOVARTIS AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia OU, Shifeng Pan, Tetsuo Uno, Yongqin Wan, Xing Wang
-
Patent number: 9624520Abstract: Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analog, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.Type: GrantFiled: May 15, 2014Date of Patent: April 18, 2017Assignee: Novartis AGInventors: Bernhard Geierstanger, Weijia Ou, Susan E. Cellitti, Tetsuo Uno, Tiffany Crossgrove, Hsien-Po Chiu, Jan Grunewald, Xueshi Hao
-
Patent number: 9585970Abstract: The present invention provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.Type: GrantFiled: May 31, 2013Date of Patent: March 7, 2017Assignee: Novartis AGInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya
-
Publication number: 20160311853Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.Type: ApplicationFiled: December 17, 2014Publication date: October 27, 2016Applicant: NOVARTIS AGInventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG, Yunho JIN
-
Publication number: 20150104468Abstract: The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.Type: ApplicationFiled: May 31, 2013Publication date: April 16, 2015Applicant: IRM LLCInventors: Bernhard Hubert Geierstanger, Jan Grunewald, Badry Bursulaya
-
Publication number: 20140302553Abstract: Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analogue, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.Type: ApplicationFiled: May 15, 2014Publication date: October 9, 2014Applicant: IRM LLCInventors: Bernhard GEIERSTANGER, Weijia OU, Susan E. CELLITTI, Tetsuo UNO, Tiffany CROSSGROVE, Hsien-Po CHIU, Jan GRUNEWALD, Xueshi HAO
-
Patent number: 8785151Abstract: Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analogue, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.Type: GrantFiled: October 23, 2009Date of Patent: July 22, 2014Inventors: Bernhard Geierstanger, Weijia Ou, Susan E. Cellitti, Tetsuo Uno, Tiffany Crossgrove, Hsien-Po Chiu, Jan Grunewald, Xueshi Hao
-
Publication number: 20140065171Abstract: The present invention provides methods of site-specific labeling of antibodies, using proteins having 4?-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates.Type: ApplicationFiled: May 31, 2013Publication date: March 6, 2014Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Badry BURSULAYA
-
Patent number: 8318172Abstract: The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety.Type: GrantFiled: February 7, 2009Date of Patent: November 27, 2012Assignee: The Scripps Research InstituteInventors: Jan Grunewald, Meng-Lin Tsao, Roshan Perera, Richard A. Lerner, Vaughn V. Smider, Peter G. Schultz